



UMC Utrecht

# How to follow treatment guidelines in different resource settings

ESGVH Postgraduate Educational Course on Viral Hepatitis

Joop Arends MD, PhD

Department of Internal Medicine & Infectious Diseases

University Medical Center Utrecht


Chair European Study Group for Viral Hepatitis (ESGVH)



Universair Medisch Centrum Utrecht

# Hepatitis Boring

ESCMID Online Lecture Library  
© by author






# perfectovir<sup>®</sup>

- pangenotypic
- 100% SVR
- No side-effects
- Short treatment duration
- cheap

# Changes in HCV treatment



# Uptodate Dutch guideline (“Richtsnoer”)

- cooperation between different specialties
- every 3 months updated
- online available



[www.hcvrichtsnoer.nl](http://www.hcvrichtsnoer.nl)





# Example of how what it looks like

## 4. Behandelvoorstel onbehandelde (naïeve) patiënten

Genotype	Regime (de behandelopties staan op alfabetische volgorde weergegeven)					
	Non-cirrose (≤F3)	EASL	AASLD	Cirrose (CP-A)	EASL	AASLD
1a†	DAC+SOF 12 LDP+SOF 12 PTV/r+OBV+DSV+RBV 12 SIM+SOF 12	A1 A1 A1 A1	IB IA IA IA	DAC+SOF+RBV 12* LDP+SOF 12 PTV/r+OBV+DSV+RBV 24 SIM+SOF+RBV 12*	B1 - A1 B1	IIaB IA IA IA
1b†	DAC+SOF 12 LDP+SOF 12 PTV/r+OBV+DSV 12 SIM+SOF 12	A1 A1 A1 A1	IB IA IA IA	DAC+SOF+RBV 12* LDP+SOF 12 PTV/r+OBV+DSV 12 SIM+SOF+RBV 12*	B1 - A1 B1	IIaB IA IA IA
2	DAC+SOF 12 SOF+RBV 12	B2 A1	IIaB IA	DAC+SOF 16 SOF+RBV 16	B1 B1	IIaB IIbC
3	DAC+SOF 12 SOF+PR 12 SOF+RBV 24	A1 B1 A1	IA IA IA	DAC+SOF+RBV 24 SOF+PR 12 SOF+RBV 24	B1 B1 A1	IIaB IA IA
4†	DAC+SOF 12 LDP+SOF 12 PTV/r+OBV+RBV 12 SIM+SOF 12	B2 A1 A1 B2	- IIaB IA -	DAC+SOF+RBV 12* LDP+SOF 12 PTV/r+OBV+RBV 12 SIM+SOF+RBV 12*	B2 B1 B1 B2	- IIaB IB -
5	LDP+SOF 12 SOF+PR 12	B1 B1	IIaB IIaB	LDP+SOF+RBV 12* SOF+PR 12	B1 B1	IIaB IIaB
6	LDP+SOF 12 SOF+PR 12	B1 B1	IIaB IIaB	LDP+SOF+RBV 12* SOF+PR 12	B1 B1	IIaB IIaB

\* In principe gaat de voorkeur uit naar een behandelduur van 12 weken met toevoeging van ribavirine. Indien er sprake is van ribavirine intolerantie kan worden overwogen om de behandelduur naar 24 weken te verlengen.

† Bij verwachte gelijke effectiviteit in geval van G1 of G4, kunnen kosten een rol spelen in keuze voor therapie (zie blz 11).

[index.html](#)


## Availability and cost of DAAs in the Netherlands

	Sofosbuvir (SOF)	Simeprevir (SIM)	Daclatasvir (DAC)	Ledipasvir/Sofosbuvir (LDP/SOF)	Paritaprevir/ritonavir/Ombitasvir (PTV/r + OBV) +/- Dasabuvir (DSV)	Ribavirine (RBV)
<b>brand name</b>	Sovaldi	Olysio	Daklinza	Harvoni	Viekirax +/- Exviera	Ribavirin
<b>Price/ 12 weeks</b>	€ 43.461	€ 25.572	€ 27.030	€ 48.759	Viekirax (€38.423) & Exviera (€3.341)	€ 516 - € 620

**Secret price arrangements have been negotiated between the pharmaceutical industry and the government**



# Cascade of care for HIV/HCV coinfecting patients





## New challenging projects

- **retrieval**
- **screening**

ESCMID Online Lecture Library  
© by author



## In conclusion

### From endemic to import disease

- 1866 cholera
- 1959 malaria
- 2020 (?) hepatitis C

